[b]Pfizer's[/b] experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said. The [b]US Food and Drug Administration[/b] has granted 'breakthrough' status for [b]Palbociclib[/b]. But, according to Mace Rothenberg, CMO for Pfizer's oncology unit, the company is still discussing a regulatory pathway for the drug and has not decided whether to seek accelerated approval.
[link url=http://www.reuters.com/article/2014/04/06/us-cancer-pfizer-idUSBREA350BJ20140406] Reuters Health[/link]